The U.S. Department of Health & Human Services (HHS) has recommended that marijuana be moved from Schedule I to Schedule III under federal law. This decision has widespread implications for the cannabis market's trajectory in 2024, touching on diverse areas ranging from policy and business to the very science underpinning such classifications. The change in classification is not just a regulatory adjustment. For stakeholders in the cannabis industry, this decision signifies an acknowledgment of